Figure 2.
Clinical Trial Landscape for Personalized TCVs
(A–K) Twenty-three personalized TCVs currently in phase 1 or 2 from 13 major sponsors: (A) trials per sponsor; (B) type of vaccine; (C) phase of trial; (D) number of antigens; (E) indication; (F) combination partner; (G) route of administration; (H) delivery system; (I) vaccine administration frequency; (J) vaccine doses per year; and (K) number of vaccine dose levels tested.